UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): March 4, 2013
DYAX
CORP.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware |
000-24537 |
04-3053198 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
55 Network Drive |
|
(Address of Principal Executive Offices) (Zip Code) |
(617) 225-2500
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 8, 2013, Dyax Corp. announced that Ivana Magovcevic-Liebisch, Ph.D., J.D., Dyax’s Executive Vice President and Chief Operating Officer, is leaving to pursue a senior management opportunity at a multinational pharmaceutical company, effective on March 29, 2013. Dr. Magovcevic-Liebisch will continue to serve the Company as a consultant following her departure.
| Item 7.01 | Regulation FD Disclosure. |
A copy of the press release announcing Dr. Magovcevic-Liebisch’s departure is furnished as Exhibit 99.1 to this report.
| Item 8.01 | Other Events. |
On March 6, 2013, Dr. Magovcevic-Liebisch sold 215,359 shares of Dyax common stock. This sale was made independently by an investment professional in an automatic transaction triggered by the occurrence of price limits previously established pursuant to a Rule 10b5-1 plan entered into by Dr. Magovcevic-Liebisch in July 2012.
| Item 9.01. | Financial Statements and Exhibits. | |
| (d) | Exhibits. | |
| 99.1 | Press release of Dyax Corp. dated March 8, 2013 reporting a management change. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DYAX CORP. |
||||
|
|
||||
|
Dated: |
March 8, 2013 | By: |
/s/ Gustav Christensen |
|
|
Gustav Christensen |
||||
|
Chief Executive Officer and President |
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
|
99.1 |
Press release of Dyax Corp. dated March 8, 2013 reporting a management change. |
Exhibit 99.1
Dyax Announces Management Change
Ivana Magovcevic-Liebisch, Ph.D., J.D., Executive Vice President, Chief Operating Officer, to Leave the Company
BURLINGTON, Mass.--(BUSINESS WIRE)--March 8, 2013--Dyax Corp. (NASDAQ: DYAX) today announced that Ivana Magovcevic-Liebisch, Ph.D., J.D., Executive Vice President, Chief Operating Officer, will leave the Company to pursue a senior management opportunity at a multinational pharmaceutical company, effective March 29, 2013. Dr. Magovcevic-Liebisch will continue to serve the Company as a consultant following her departure.
“The Board and I wish to express our gratitude to Ivana for her outstanding contributions and service to Dyax,” said Gustav Christensen, President and Chief Executive Officer of Dyax Corp. “She has played an important role in building Dyax into a successful commercial company and has helped establish an internal organization that is well-equipped to advance the Company’s strategy moving forward.”
Dr. Magovcevic-Liebisch commented: “I am grateful for my twelve year tenure at Dyax. During this time, we have built an outstanding team that will continue to execute the Company’s business plan and build significant value. I look forward to working with the team through the transition period.”
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.
The Company is currently developing products to expand its angioedema portfolio, including a suite of diagnostic assays to identify plasma kallikrein mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for the prophylactic treatment of HAE and other PKM angioedemas.
KALBITOR and DX-2930 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 13 royalty and/or milestone bearing product candidates in various stages of clinical development, including three in Phase 3 trials.
Dyax is headquartered in Burlington, Massachusetts. For additional information about Dyax, please visit www.dyax.com.
CONTACT:
Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate
Director, Investor Relations and
Corporate Communications
jrobinson@dyax.com